Truist analyst Joon Lee initiated coverage of Larimar Therapeutics (LRMR) with a Buy rating and $18 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LRMR:
- Larimar Therapeutics Aligns Executive Incentives with Milestones
- Market ‘misinterpreting’ Larimar data, selloff ‘overdone,’ says Citi
- Larimar Therapeutics selloff a buying opportunity, says JonesResearch
- Larimar Therapeutics trading resumes
- Larimar Therapeutics trading halted, volatility trading pause